Where Pacira BioSciences Stands With Analysts
Pacira BioSciences (NASDAQ:PCRX) has observed the following analyst ratings within the last quarter:
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $84
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $80 to $84.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $80
HC Wainwright & Co. analyst Oren Livnat maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $84 to $80.
Pacira Beefs Up Non-Opioid Pain Management Via Flexion Acquisition
Pacira BioSciences Inc (NASDAQ:PCRX) has agreed to acquire Flexion Therapeutics Inc (NASDAQ:FLXN) for $8.50 per share in cash, plus one contingent value…
Pacira BioSciences To Host Investor Day On Oct. 15, 2021 In Tampa. Florida
Pacira BioSciences, Inc. (NASDAQ:PCRX) the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it will host an Investor Day on Friday, October 15,
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
Barclays Maintains Overweight on Pacira BioSciences, Lowers Price Target to $91
Barclays analyst Balaji Prasad maintains Pacira BioSciences (NASDAQ:PCRX) with a Overweight and lowers the price target from $95 to $91.
Pacira Announces Commercial Production Underway With Enhanced EXPAREL Manufacturing Process At Swindon Facility
Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it has successfully completed process validation and